US Bancorp
INKT icon

US Bancorp’s MiNK Therapeutics INKT Stock Holding History

US Bancorp’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.3K Buy
+1,995
New +$23.2K ﹤0.01% 3152

Other funds holding INKT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
PP
Paladin Partners Hartland, Wisconsin $151M AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

US Bancorp's INKT Position: Q2 2026 in Review

US Bancorp opened a new position in MiNK Therapeutics (INKT) in Q2 2026: 1,995 shares worth $23.3K. The stake represents ﹤0.01% of the portfolio and ranks #3152 among its holdings.

22 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • US Bancorp held 1,995 shares of MiNK Therapeutics worth $23.3K as of Q2 2026.
  • MiNK Therapeutics was a new US Bancorp position in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3152 holding.
  • 22 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.